SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000909661-06-000004
Filing Date
2006-01-11
Accepted
2006-01-11 16:14:59
Documents
1
Group Members
CHARLES E. ELLWEINCHUN R. DINGDEREK C. SCHRIERFARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.FARALLON CAPITAL OFFSHORE INVESTORS II, L.P.FARALLON CAPITAL PARTNE

Document Format Files

Seq Description Document Type Size
1 amylin13ga2.txt SC 13G/A 82086
  Complete submission text file 0000909661-06-000004.txt   85242
Mailing Address 9360 TOWNE CENTRE DR SUITE 110 SAN DIEGO CA 92121
Business Address 9360 TOWNE CENTRE DR SUITE 110 SAN DIEGO CA 92121 6195522200
AMYLIN PHARMACEUTICALS INC (Subject) CIK: 0000881464 (see all company filings)

IRS No.: 330266089 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-42168 | Film No.: 06525016
SIC: 2834 Pharmaceutical Preparations

Mailing Address ONE MARITIME PLAZA SAN FRANCISCO CA 94111
Business Address ONE MARITIME PLAZA STE 11325 SAN FRANCISCO CA 94111 4154212132
FARALLON CAPITAL MANAGEMENT LLC (Filed by) CIK: 0000909661 (see all company filings)

IRS No.: 943240279
Type: SC 13G/A